Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations

Life Sciences, Endocrinology, Physiology +10

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

Medicine, Endocrinology, Internal Medicine +15

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Cathrine Ørskov, L. Rabenhøj, André Wettergren et al. · Diabetes · 1994 · 892 citations

Life Sciences, Endocrinology, Pharmacokinetics +5

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

M. Gutniak, Jens J. Holst, Bo Åhrén et al. · New England Journal of Medicine · 1992 · 875 citations · Full text

Medicine, Endocrinology, Pharmacology +17